NextCell Pharma AB

kr 0.28As of Sun 8 Nov 2026, 12:00 UTC
STO:NXTCLHealthcare
Country Sweden
PE (Fwd) •••
TSR 9Y CAGR (21.58%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.77
PE TTM —
TSR TTM (68.86%)
Mkt cap kr 35.58M
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 0.31
10.13%
(63.11%)
Hold 8|10|9|0|9
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
—
—
—
—
20.03%
29.66%
24.72%
18.31%
Revenuekr M
2.072
2.116
2.225
2.281
5.18%
3.57%
5.34%
9.39%
Peers (US$3.597M)
Cap (US$)
PE
3.889M
13.77x
3.638M
18.36x
Capital
TTM
5Y
10Y
Leveragex
0.799
1.199
1.040
EBIT/Intx
0.982
0.171
0.176
Own earn%
(58.57)
(62.29)
(55.59)
Sh yield%
39.94
26.63
28.68
Owners
Insiders/Inst%
9.83
61.04
Short interest%
2.46
SBC / revenue%
3.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
11–17
$1 testx
0.0
Incr. ROIC%
1